Vanda Pharmaceuticals Stock
Vanda Pharmaceuticals Stock
Vanda Pharmaceuticals dominated the market today, gaining €0.14 (3.350%).
Currently there is a rather positive sentiment for Vanda Pharmaceuticals with 4 Buy predictions and 0 Sell predictions.
With a target price of 5 € there is a slightly positive potential of 15.74% for Vanda Pharmaceuticals compared to the current price of 4.32 €.
So far the community has only identified positive things for Vanda Pharmaceuticals stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Vanda Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vanda Pharmaceuticals vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Vanda Pharmaceuticals | 3.350% | -10.000% | 20.670% | -24.211% | 11.340% | -69.577% | - |
Ardelyx Inc. | 3.600% | -1.640% | -12.849% | 41.749% | 3.737% | -16.140% | - |
Salarius Pharmaceuticals Inc. | 1.400% | 3.333% | 6.373% | -63.833% | -21.802% | -98.281% | -99.993% |
Brainstorm Cell | -5.760% | -2.456% | -18.607% | -82.011% | 114.009% | -83.339% | - |
Comments
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Show more
Ratings data for VNDA provided by MarketBeat